Arabian companies will start selling Sangui products in the course of next few months
Exhibit
99.46
Sangui
BioTech International, Inc.
0000
Xxxxx Xxxxxxx Xxxxxx
Xxxxxxxxxx, Xxxx 00000
Xxxxxxxxxx, Xxxx 00000
x/x
XxxxxxXxxXxxx XxxX
Xxxxxx-Xxxxxxxxxx-Xxx.
00
00000
Xxxxxx
Arabian
companies will start selling Sangui products in the course of next few
months
Witten,
Dubai, May 23, 2007 – Comprehensive marketing and distribution agreements to
this effect have been signed between Sheikh Al
Mudhareb, TYCOON Consulting (UK) Ltd. and SanguiBioTech GmbH after a
series of presentations and in depth negotiations in Sharjah and Dubai. Products
covered by the terms of the contracts include the whole range of Sangui’s
present and future cosmetics products as well as the range of medical products
if and when certified for distribution in these markets. This refers in
particular to Sangui’s ChitoSkin wound pads based on bovine gelatine and the
HemoSpray based on camel blood.
The
agreements extend to a number of Arabian and Muslim countries
including the United Arab Emirates, Saudi-Arabia, Kuwait, Oman,
Yemen, Sudan, Jordan, Libya, Lebanon, Marocco, Malaysia, India and
Turkey, granting the partner firms exclusive distribution rights for
those markets. Discussions for similar agreements regarding Egypt are currently
under way. Based on the current volume and pricing scheme which was discussed
and agreed upon Sangui expects its cosmetics sales alone and based on the
present portfolio to reach € 875.000 in 2007, € 1.750.000 in 2008 and €
3.500.000 in 2009. To this, any additional sales of future cosmetic products
as
well as medical products would be added.
It
is
understood by all parties concerned, that Sangui’s unique products merit special
marketing activities, and to this end the requisite TV and complimentary
advertising strategies will be developed in collaboration with Sangui to
ensure
that a precise product message is conveyed to the customer.
“These
marketing contracts follow exactly the road map of our initial agreement
of
Febr. 7th and open more or less the entire scope of Arabian markets for Sangui’s
products”, Xxxxxxx Xxxxxx, TYCOON Chairman, and Xxxxxxxx Xxxxxxx, Sangui
Managing Director, emphasized. “As the financial standing and marketing
competence of our local partners is beyond any doubt, we are looking forward
to
a very exciting future.”
Meanwhile,
paperwork and discussions pertaining to the planned acquisition of 25% of
SanguiBioTech GmbH by TYCOON VCI are on schedule.
SanguiBioTech
GmbH is a wholly owned subsidiary of Sangui BioTech International, Inc.
(xxx.xxxxxxxxxx.xxx: SGBI)
For
more
information please contact:
Joachim
Fleing
Phone:
x00 (000) 000 00 00
Fax:
+49
(2302) 915 191
e-mail:
xxxxxx@xxxxxx.xx
Some
of
the statements contained in this news release discuss future expectations,
contain projection of results of operation or financial condition or state
other
“forward-looking” information. These statements are subject to known
and unknown risks, uncertainties, and other factors that could cause the actual
results to differ materially from those contemplated by the
statements. The forward-looking information is based on various
factors and is derived using numerous assumptions. Important factors
that may cause actual results to differ from projections include, among many
others, the ability of the Company to raise sufficient capital to meet operating
requirement.
Words
such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,”
“estimates,” and variations of such words and similar expressions are intended
to identify such forward-looking statements. Unless required by law,
the Company undertakes no obligation to update publicly any forward-looking
statements, whether as a result of new information, future events or
otherwise.
